#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ependymoma Methylmalonic acidaemia Fontan procedure Familial hypertriglyceridaemia Polymyositis Extraskeletal ossification Optic glioma Non-small cell lung cancer metastatic Gastrointestinal stromal tumour Bulbospinal muscular atrophy congenital Congenital myopathy Adenomatous polyposis coli Chondrosarcoma metastatic Thalassaemia alpha Usher's syndrome More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency – Life with Disease Congenital hypotransferrinaemia – Diagnostics Hereditary hypophosphataemic rickets – Trials in Disease Erdheim-Chester disease – Trials in Disease Erdheim-Chester disease Mantle cell lymphoma – Diagnostics Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Focal segmental glomerulosclerosis – Life with Disease Brain stem glioma – Trials in Disease Mantle cell lymphoma refractory – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    99MTC-EUK-(SO3)CY5-MAS3 APAZUNERSEN Acetazolamide Sodium Sunvozertinib Sorafenib Hct116-A ISPAGHULA HUSK Glibenclamide Keto-Isoleucine Calcium Clonazepam Cedazuridine Corylus Avellana L. Efpegerglucagon Mva-209-Fsp-B4 Pimozide Mercaptopurine Levamisole Hydrochloride Trospium Chloride Hydroxocobalamin Jab-21822 More therapies…

    Learn about Your Condition

    Angiosarcoma recurrent Pelvic venous thrombosis T-cell type acute leukaemia Endometrial adenocarcinoma Senile dementia Alveolar proteinosis Thymoma malignant Uterine leiomyoma Lipid metabolism disorder Antisynthetase syndrome Lymphangioma Arginase deficiency Primary hyperoxaluria Apheresis Myocarditis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myelofibrosis

  • Study on Extended Access to Momelotinib for Patients with Myelofibrosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • Momelotinib Dihydrochloride Monohydrate
    Belgium Bulgaria Denmark France Germany Hungary +4

  • Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Netupitant
    • Aprepitant
    • Palonosetron
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • 2-(3-(3,5-Dimethyltriazol-4-Yl)-5-((S)-Oxan-4-Yl(Phenyl)Methyl)Pyrido(3,2-B)Indol-7-Yl)Propan-2-Ol
    • Fedratinib
    • Ruxolitinib
    France Germany Greece Italy Poland Romania +1

  • Continued Treatment Study for Patients with Myelofibrosis, Post-Lung Transplant BOS, or Chronic Graft-Versus-Host Disease Using Itacitinib

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Chronic graft versus host disease
    • Myelofibrosis
    Investigated Drugs:
    • Itacitinib
    Austria Belgium Germany Greece Italy Spain

  • Study of Fedratinib and Nivolumab for Patients with Myelofibrosis Resistant to JAK-inhibitor Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • Fedratinib
    • Nivolumab
    Germany

  • Study of Selinexor for Patients with Previously Treated Myelofibrosis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • Selinexor
    Italy Spain
Previous Page
1 … 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!